Entering text into the input field will update the search result below

Verastem: New Assets, New Indications

Apr. 09, 2021 9:12 AM ETVerastem, Inc. (VSTM)5 Comments


  • Verastem monetised its approved asset Copiktra and now has a decent cash runway.
  • Last year, it acquired new assets that it is running through trials.
  • Trial completion is 3-4 years away.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Natural Killer Cell (NK Cell) destroying a cancer cell
Photo by Marcin Klapczynski/iStock via Getty Images

I covered Verastem (NASDAQ:VSTM) a few years ago, when they were running duvelisib through the PDUFA. That molecule, now called Copiktra, got approved in 2018 for the following indications:

For adult patients

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

EagleFirst profile picture
You failed to mention the all important investigator-initiated FRAME study which has generated early but highly encouraging indications to the future of the two phase 2 registration-directed clinical studies, with update from the Frame study in the NSCLC cohort to be reported at the 2021 American Association for Cancer Research Annual Meeting as well as an update from the Frame study in the LGSOC cohort in the second half of 2021.

Nice write up. What is your best biotech stock idea today?
seekingAplha1982 profile picture
So no data expected this year, but stock still trading pretty high for that. Should be a Penny stock or around $1
@seekingAplha1982 completely random statement...market cap is what matters and this will double within 12 months on pipeline, momentum.
EagleFirst profile picture
@seekingAplha1982 Please read company's recent news release. Please.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About VSTM

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VSTM

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.